BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Proteolix, Inc. 

225 Gateway Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-866-6351 Fax: 650-866-6356


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Proteolix, Inc. discovers and develops pharmaceutical products that target certain cancers and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. Our lead product candidate, carfilzomib (PR-171), is currently in multiple clinical trials to evaluate its safety and efficacy for the treatment of multiple myeloma, lymphoma and certain solid tumor malignancies. In addition, Proteolix is developing next generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this new target class.

Proteolix is privately-held and headquartered in South San Francisco.


 Key Statistics


Email: info@proteolix.com
Ownership:

Web Site: Proteolix, Inc.
Employees:
Symbol: 
 









 Company News
Proteolix, Inc. to Present Preclinical Data on Carfilzomib and PR-957 at the 2009 ACR/ARHP Annual Meeting 10/19/2009 9:10:17 AM
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 6/15/2009 9:38:57 AM
Proteolix, Inc. Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association 6/8/2009 10:45:01 AM
Proteolix, Inc. Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 American Society of Clinical Oncology Annual Meeting 6/2/2009 10:43:14 AM
Proteolix, Inc. Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 American Society of Clinical Oncology Annual Meeting 6/1/2009 11:12:25 AM
Proteolix, Inc. to Present Carfilzomib Clinical Data During the 2009 American Society of Clinical Oncology Annual Meeting 5/15/2009 10:15:09 AM
Proteolix, Inc. Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team 4/16/2009 11:48:53 AM
Proteolix, Inc. Announces the Appointment of John Scarlett, M.D., President and CEO 2/25/2009 7:30:44 AM
Proteolix, Inc. Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma 12/9/2008 8:23:37 AM
Proteolix, Inc. Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology 12/8/2008 12:46:27 PM
123